Faron Pharmaceuticals Ltd (LON:FARN) has said a scientist leading a trial of its early-stage immuno-oncology drug will provide more context on the treatment's “promising” anti-tumour activity at a leading industry conference.
Dr Petri Bono, principal investigator heading the phase I/II MATINS study of bexmarilimab, will also provide commentary around the drug’s potential efficacy.
His team has observed a long-lasting partial response in a person with metastatic colorectal cancer and target lesion responses from “heavily pre-treated” melanoma and ovarian cancer patients.
Bono’s team took on difficult to treat, end of line cases. For example, the colorectal cancer patient had received six different regimens before receiving bexmarilimab.
The lead investigator will present data on 30 people from which the Faron team observed sustained pharmacodynamic effects from the treatment.
Bexmarilimab was also deemed to have very good tolerability across all dosing levels with no observed dose-limiting toxicity.
Noted also in the data was the conversion of cold tumours that traditionally do not provoke a strong response from the immune system into inflamed hot tumours, which do.
Bono will present the update to the European Society of Medical Oncology Virtual Congress later Friday.
In a statement, he said: "The emerging tolerability profile and evidence of clinical anti-tumour activity for this novel anti Clever-1 antibody are promising.
“These data are from patients with difficult-to-treat cancers who had already failed all standard therapy options and received as many as six different lines of therapy, exhausting all future treatment options.
“As this trial continues, we will learn more about this novel immunotherapy's potential to help those cancer patients who desperately need new treatment options."